Thousand Oaks apartment complex sells for $67 million
A 191-unit multifamily community at 491 W. Gainsborough Road in Thousand Oaks sold for $67 million. Pacific Urban Residential bought the property from IMT Capital LLC, according to Greg Harris of Marcus & Millichap who coordinated the deal. “The acquisition provided the buyer with the opportunity to enter a highly coveted market supported by the Read More →
Amgen partners with Swedish company to develop drugs
Thousand Oaks-based Amgen will pay a Swedish company up to $410 million to help it develop oncology and neuroscience drugs. The companies announced the partnership Oct. 4 and said Nuevolution will use its Chemetics drug discovery platform to discover drugs for Amgen. Nuevolution may receive licensing payments along with development, commercial and milestone payments. It Read More →
Amgen leukemia drug cures 39 percent of treated patients, study finds
Amgen’s new leukemia drug cured 39 percent of pediatric patients who received treatment, the Thousand Oaks company said Oct. 3 after publishing results of a new study in the Journal of Clinical Oncology. Blincyto, which treats a rare form of the disease known as precursor B-cell acute lymphoblastic leukemia, sent 27 patients out of 70 Read More →
CoastHills Credit Union opens branch in Thousand Oaks
Lompoc-based CoastHills Credit Union recently opened its first Ventura County branch at 125 N. Moorpark Road in Thousand Oaks. The 5,000-square-foot “branch of the future” features a virtual banking experience as well as a tech bar that offers tutorials for CoastHill’s digital products. CoastHills completed a renovation of the space that was formerly home to Read More →
Miramar resort redevelopment expected to be finished in 2018
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
FDA gives big win to Amgen in biosimilars race
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen paying Arrowhead for traits to develop cardiovascular drugs
Amgen will license two traits from a Pasadena pharmaceutical company to develop cardiovascular drugs under a partnership announced Sept. 29. Under the agreement, Thousand Oaks-based Amgen will pay Arrowhead Pharmaceuticals $35 million up front, $21.5 million in the form of an equity investment by Amgen in Arrowhead common stock, and up to $617 million in Read More →
